Pfizer pays $485 million for Xiaflex
This article was originally published in Scrip
Executive Summary
Pfizer is to pay Auxilium Pharmaceuticals up to $485 million to buy the European rights to its potential blockbuster Xiaflex (clostridial collagenase). The product is a first-in-class late-stage biologic for Dupuytren's contracture and Peyronie's disease.